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Abstract 
The use of therapeutic drug monitoring (TDM) when prescribing antipsychotics is not yet considered 
a routine care procedure, despite evidence and opinion regarding its benefit. Amongst the 
arguments against the inclusion of TDM, are the many logistical deficiencies that prevent the TDM 
service from being as optimal as warranted. It has been identified that improvements within the 
service being offered for TDM may result in improvements with the overall TDM practice; which may 
result in an increase usage. It was recognised that altering the analysis technique to a faster, more 
versatile process, may be impacting on the overall service that could be offered and thus improve 
the holistic practice of TDM of antipsychotics. Capillary electrophoresis (CE) was chosen for 
consideration as an alternate analysis technique, primarily due to the known ability of this technique 
to achieve fast separations of structurally similar compounds and its ability to be readily 
implemented in small potentially portable lab-on-a-chip devices. It was therefore the aim of this 
thesis to develop and consider CE methods for the analysis of antipsychotics for the intended 
application of TDM. 
The development of CE methods was performed in a step-wise manner, through an understanding 
of the applications use. The first method developed was aimed at a secondary application of TDM 
of compliance monitoring and achieved through an extensive examination of a multivariate 
optimisation of separation parameters using the modelling software known as Peakmaster. Through 
this work a set of parameters was identified that allowed for the separation of 17 antipsychotics 
within 5 minutes. The optimal method was subsequently validated for evaluation and found to be 
analytical suitable for consideration within a compliance monitoring setting. In addition, the 
developed separation was successfully adapted for compatibility with a mass spectrometer detector 
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(CE-MS), however this was not considered appropriate for clinical application at this stage due to 
instrumental weakness observed during this work. 
The second stage of focus was to progress the method development specifically towards TOM 
appropriate applications. This was achieved by developing the first separation for aripiprazole and 
both main metabolites. Here a separation was achieved for three structurally similar compounds 
within nine minutes and found to be ideal for the intended application of TOM. Having successfully 
developed aCE method suitable for TOM, the final method was developed with the aim of 
incorporating the two positive elements of the prior two methods: many compounds within one 
method and achieve separation of structurally similar compounds. Consequently a method was 
developed incorporating five popularly prescribed antipsychotics and metabolites, resulting in a 
separation of 13 compounds within eight minutes. 
The methods developed and presented within this thesis were considered suitable for the intended 
application of TOM. Due to the speed and resolution achieved within the separations, it was 
foreseeable that the implementation of these methods would have the potential of improving the 
versatility of the TOM service and therefore potentially improve the usage of TOM for antipsychotics. 
It was clearly acknowledged that further assessment would be necessary (such as tandem testing) 
before suggesting these methods be implemented. However the work here supports the idea of 
changing the analytical technique employed for the process of TOM of antipsychotics to CE, as a 
modification that would allow for improvements to the overall service delivered. 
Page X 
Publications and Presentations 
Publications 
K. F. Johns, et al., 2009 Evaluation of Peakmaster for computer aided multivariate optimisation of a 
CE separation of 17 antipsychotic drugs using minimal experimental data. Electrophoresis. 30(5): p. 
839-847. 
Presentations 
IATDMCT lOth International congress 
Nice, France, September 2007 
Poster entitled: Monitoring of Anti-Psychotics: improving the analytical methodology for compliance 
and therapeutic drug monitoring with capillary electrophoresis-mass spectrometry. 
19th International Symposium on Pharmaceutical and Biomedical Analysis (PBA) 
Gdansk, Poland, June 2008 
Poster entitled: Computer aided multivariate optimization of a capillary electrophoresis separation 
of 17 anti-psychotics for compliance monitoring. 
Page XI 
